Drugs / SHR0532
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03971929 | Jul 2019 → Sep 2020 | hypertensive disorder | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03645278 | Aug → Dec 2018 | hypertensive disorder | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR 0532 | “A Phase I, Randomized, Double-Blind, Placebo-hydrochlorothiazide Parallel Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Efficacy of SHR 0532 Oral Tablets in...” NCT03971929 ↗ |
| Route | Oral | “single dose of oral SHR0532 tablet.” NCT03645278 ↗ |